Ebi O
Takeda Chemical Ind., Ltd., Tokyo, Japan.
Gan To Kagaku Ryoho. 1998 Apr;25(5):650-62.
The new Japanese GCP enacted on the basis of ICH-GCP adopts more clear concepts of quality assurance for a clinical trial. This article briefly describes its principles. Sponsors are now responsible not only for initiation but also for management of clinical trials. Thus, discussions have been under taken the points to be considered in, among others, imple mentation/maintenance of the Quality Assurance/ Control systems, preparation/amendment of a clinical trial protocol, entrusting to a coordinating investigator/committee, monitoring, audit, and direct access to source documents and all other trial-related records. Further, this addresses the required reorganization which the sponsor should strive for as well as the sponsor's requests to participating medical institutions such as adoption of a "study coordinator". To improve the quality of a clinical trial, it would be necessary to refer not only to GCP but also to other current guidelines such as those harmonized at the ICH.
基于国际人用药品注册技术协调会(ICH)-药品临床试验管理规范(GCP)制定的新版日本GCP,采用了更为清晰的临床试验质量保证概念。本文简要介绍其原则。申办者现在不仅要负责启动临床试验,还要负责管理临床试验。因此,已经就以下要点展开了讨论,包括质量保证/控制系统的实施/维护、临床试验方案的制定/修订、委托给协调研究者/委员会、监查、稽查以及直接获取源文件和所有其他试验相关记录等。此外,本文还阐述了申办者应努力进行的必要重组以及申办者对参与的医疗机构提出的要求,比如采用“研究协调员”。为提高临床试验质量,不仅有必要参考GCP,还需参考其他现行指南,如ICH协调统一的指南。